Vaccination with lipopolysaccharide isolated from the live vaccine strain of Francisella tularensis protects against murine tularemia

A. H. Fortier, R. B. Narayanan, Joseph Drabick, J. C. Williams, C. A. Nacy

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A monoclonal antibody (mAb) prepared against the lipopolysaccharide (LPS) of Francisella tularensis was inoculated into mice 2 h prior to challenge with 1000 LD50 F. tularensis, the live vaccine strain (LVS). Mice treated with 2-mg mAb survived the challenge inoculum. Successful passive transfer of protection by the anti-LPS monoclonal led us to explore the active vaccine potential of LPS extracted from F. tularensis strain LVS. Mice immunized with LVS-LPS generated Ab that recognized phenol water extracted LPS from Francisella, as well as whole F. tularensis LVS bacteria. Ab did not crossreact with Escherichia coli, Yersinia enterocolitica, or Brucella abortus, but did react with the virulent SCHU-4 strain of F. tularensis. LVS-LPS immunized mice were protected from challenge with 103 LD50 F tularensis LVS inoculated intraperitoneally and 107 F. tularensis LVS inoculated intradermally, but were not protected against lethal challenge with an unrelated gram-negative organism, E. coli BORT.

Original languageEnglish (US)
Pages (from-to)193-202
Number of pages10
JournalVaccine Research
Volume5
Issue number4
StatePublished - Dec 1 1996

Fingerprint

Francisella tularensis
Tularemia
Lipopolysaccharides
Vaccination
Vaccines
Lethal Dose 50
Francisella
Monoclonal Antibodies
Escherichia coli
Brucella abortus
Yersinia enterocolitica
Phenol
Bacteria
Water

All Science Journal Classification (ASJC) codes

  • Immunology
  • Microbiology (medical)

Cite this

@article{f47211f217864f9195a75bbfee89f55a,
title = "Vaccination with lipopolysaccharide isolated from the live vaccine strain of Francisella tularensis protects against murine tularemia",
abstract = "A monoclonal antibody (mAb) prepared against the lipopolysaccharide (LPS) of Francisella tularensis was inoculated into mice 2 h prior to challenge with 1000 LD50 F. tularensis, the live vaccine strain (LVS). Mice treated with 2-mg mAb survived the challenge inoculum. Successful passive transfer of protection by the anti-LPS monoclonal led us to explore the active vaccine potential of LPS extracted from F. tularensis strain LVS. Mice immunized with LVS-LPS generated Ab that recognized phenol water extracted LPS from Francisella, as well as whole F. tularensis LVS bacteria. Ab did not crossreact with Escherichia coli, Yersinia enterocolitica, or Brucella abortus, but did react with the virulent SCHU-4 strain of F. tularensis. LVS-LPS immunized mice were protected from challenge with 103 LD50 F tularensis LVS inoculated intraperitoneally and 107 F. tularensis LVS inoculated intradermally, but were not protected against lethal challenge with an unrelated gram-negative organism, E. coli BORT.",
author = "Fortier, {A. H.} and Narayanan, {R. B.} and Joseph Drabick and Williams, {J. C.} and Nacy, {C. A.}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "5",
pages = "193--202",
journal = "Vaccine Research",
issn = "1056-7909",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

Vaccination with lipopolysaccharide isolated from the live vaccine strain of Francisella tularensis protects against murine tularemia. / Fortier, A. H.; Narayanan, R. B.; Drabick, Joseph; Williams, J. C.; Nacy, C. A.

In: Vaccine Research, Vol. 5, No. 4, 01.12.1996, p. 193-202.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Vaccination with lipopolysaccharide isolated from the live vaccine strain of Francisella tularensis protects against murine tularemia

AU - Fortier, A. H.

AU - Narayanan, R. B.

AU - Drabick, Joseph

AU - Williams, J. C.

AU - Nacy, C. A.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - A monoclonal antibody (mAb) prepared against the lipopolysaccharide (LPS) of Francisella tularensis was inoculated into mice 2 h prior to challenge with 1000 LD50 F. tularensis, the live vaccine strain (LVS). Mice treated with 2-mg mAb survived the challenge inoculum. Successful passive transfer of protection by the anti-LPS monoclonal led us to explore the active vaccine potential of LPS extracted from F. tularensis strain LVS. Mice immunized with LVS-LPS generated Ab that recognized phenol water extracted LPS from Francisella, as well as whole F. tularensis LVS bacteria. Ab did not crossreact with Escherichia coli, Yersinia enterocolitica, or Brucella abortus, but did react with the virulent SCHU-4 strain of F. tularensis. LVS-LPS immunized mice were protected from challenge with 103 LD50 F tularensis LVS inoculated intraperitoneally and 107 F. tularensis LVS inoculated intradermally, but were not protected against lethal challenge with an unrelated gram-negative organism, E. coli BORT.

AB - A monoclonal antibody (mAb) prepared against the lipopolysaccharide (LPS) of Francisella tularensis was inoculated into mice 2 h prior to challenge with 1000 LD50 F. tularensis, the live vaccine strain (LVS). Mice treated with 2-mg mAb survived the challenge inoculum. Successful passive transfer of protection by the anti-LPS monoclonal led us to explore the active vaccine potential of LPS extracted from F. tularensis strain LVS. Mice immunized with LVS-LPS generated Ab that recognized phenol water extracted LPS from Francisella, as well as whole F. tularensis LVS bacteria. Ab did not crossreact with Escherichia coli, Yersinia enterocolitica, or Brucella abortus, but did react with the virulent SCHU-4 strain of F. tularensis. LVS-LPS immunized mice were protected from challenge with 103 LD50 F tularensis LVS inoculated intraperitoneally and 107 F. tularensis LVS inoculated intradermally, but were not protected against lethal challenge with an unrelated gram-negative organism, E. coli BORT.

UR - http://www.scopus.com/inward/record.url?scp=0030511942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030511942&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 193

EP - 202

JO - Vaccine Research

JF - Vaccine Research

SN - 1056-7909

IS - 4

ER -